Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

Tesaro joins PARP parade with US approval of Zejula

Unlike its rivals Zejula doesn’t require a BRCA mutation in patients before use

- PMLiVE

Dr Thomas Lynch Jnr takes up new role at Bristol-Myers Squibb

Will focus on leading the firm's research and development programme

- PMLiVE

Keytruda and Opdivo backed for new uses in Europe

CHMP recommendations also include Trumenba, Dinutuximab beta and Refixia

- PMLiVE

Therachon appoints new chief medical officer

Dr Maarten Kraan joins the company from AstraZeneca

- PMLiVE

AZ gets rapid approval in China for Tagrisso

Lung cancer treatment becomes first medicine to pass through the country's Priority Review pathway

Choices, choices…

Not all innovative business models are equal

- PMLiVE

Amgen wins European approval for Humira biosimilar Amgevita

European Commission approves the first version of AbbVie's blockbuster

- PMLiVE

Merck, Pfizer get first OK for checkpoint inhibitor avelumab

FDA approval for rare skin cancer drug

Novartis day

What future for serelaxin after phase III miss?

Novartis' acute heart failure therapy misses two main endpoints

- PMLiVE

Novartis appoints new UK managing director

Haseeb Ahmad joins the firm from MSD

Precision medicine and the changing role of the healthcare professional

The growth of precision medicine introduces a shift away from treating the population as a whole, to treating each patient as an individual. How does this change the role of...

Blue Latitude Health

How will Sustainability and Transformation Plans (STPs) change the NHS commissioning landscape?

Sue Thomas and Paul Midgley, of Wilmington Healthcare, take a look at new commissioning structures and what they mean for pharma

Wilmington Healthcare

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links